Skip to content
Open access

Tumour-to-Kidney Absorbed Dose Ratios for Alpha-Emitter PRRTs Estimated with [177Lu]Lu-DOTATATE SPECT Images and Biokinetic Models: Patient Variations Impact Contribution from Redistributing Daughters.

Sep 2026 · International Journal of Radiation Oncology, Biology, Physics · 0 citations · 26 references
Medicine

TL;DR

The trend for tumour-to-kidney absorbed dose ratios should be weighed against other important aspects for radionuclide therapies, and considered with the uncertainty in the underlying assumption of equivalent biokinetics.

Abstract

INTRODUCTION Biokinetics for potential alpha-emitter peptide receptor radionuclide therapies (PRRTs) were simulated to estimate tumour-to-kidney absorbed dose ratios for 225Ac, 227Th, 212Pb, 230U, 226Ac, 211At, and 149Tb. The impact of daughter redistribution was studied, along with the effects of differing biokinetics and modelling assumptions.

Methods

Post-injection whole body probe measurements and SPECT/CT images at five and four time points, respectively, of 14 patients receiving [177Lu]Lu-DOTATATE were used to estimate whole body, tumour, and kidney time-activity curves. Alpha-emitter PRRT biokinetics were estimated by adjusting time-activity curves by the physical half-lives of parent radionuclides. Daughter redistribution was included, assuming all alpha decays and separate scenarios with 0%, 16%, 36%, and 100% of beta decays released daughters to ICRP biokinetic models. The initial conditions of the biokinetic models were changed to assess the impact of modelling assumptions. The tumour-to-kidney absorbed dose ratios were compared. Variations between patients was assessed by coefficient of variation (CoV).

Results

Inter-patient variation in whole body time-integrated activities increased with physical half-life of the parent radionuclide. For 212Pb, 225Ac, and 227Th there was large inter-patient variation in kidney absorbed dose change when incorporating daughter redistribution (absolute CoV >40%), while for 226Ac and 230U it was consistent between patients (absolute CoV <3%). Modifying the distribution in the biokinetic models impacted the kidney absorbed dose, but different modifications impacted different decay chains. Tumour-to-kidney absorbed dose ratios tended to increase with parent half-life, but for some decay chains the effect of rate of daughter release from tumours was notable.

Conclusion

The trend for tumour-to-kidney absorbed dose ratios should be weighed against other important aspects for radionuclide therapies, and considered with the uncertainty in the underlying assumption of equivalent biokinetics. The large inter-patient variations resulting from daughter redistribution for 212Pb, 225Ac, and 227Th kidney absorbed doses underline the need for representative patient cohorts.

Read PDF

Similar papers

Open access Oct 2026

Coupling target and radioactive emitter matters: a sub-tissue dosimetric study to identify optimal strategies

Radiopharmaceutical-therapy dosimetry depends on both radionuclide emission physics and the spatial distribution of activity. We evaluated how radionuclide identity and protein-defined subcellular localization influenced cancer-cell nuclear absorbed-dose distributions in one human breast-cancer region of interest...

Arvin Haj-Mirzaian, V. Onecha, Umar Mahmood et al. · 0 citations
Oct 2026

Biodistribution and dosimetry of free 118Te, an in vivo generator of the positron emitter 118Sb for long-term positron emission tomography

The limited dosimetric impact from 118Te provides justification for its use as an in vivo generator of 118Sb for long-term PET, and the ADCs reported here offer a quantitative basis for assessing the dosimetric safety of 118Te radiopharmaceuticals.

Jaewoong Jang, Sotaro Miyao, Xin-Di Qiu et al. · 0 citations
Open access Oct 2026

First-in-human dosimetry and biodistribution of [89Zr]Zr-oxine-labeled autologous leukocytes using PET/CT

The results support the further use of this approach for imaging autologous leukocytes using PET in a range of clinical and research settings and demonstrate the safety and favorable dosimetry of [89Zr]Zr-oxine-labeled leukocytes in healthy humans.

Kadir Gultekin, Jennifer L. Bartels, Carlos E. Cardenas et al. · 0 citations
Open access Nov 2026

Pharmacokinetic and dosimetric evaluation of [177Lu]Lu-FAPI for stromal-targeted radionuclide therapy in triple-negative breast cancer: a preclinical biodistribution and dosimetry study

Triple-negative breast cancer (TNBC) has limited targeted treatment options and is strongly influenced by stromal biology. This study evaluated [ 177 Lu]Lu-FAPI for fibroblast activation protein-alpha (FAP)-directed tumor microenvironment targeting in TNBC models. [ 177 Lu]Lu-FAPI was assessed usin...

Zhi-Hua Tang, Lu-Shan Yu, Ke Zhang · 0 citations
Open access Oct 2026

Multi-Cycle Dosimetry of the Albumin-Binding Prostate-Specific Membrane Antigen Ligand [177Lu]Ludotadipep in Metastatic Androgen Pathway Modulator-Resistant Prostate Cancer with Adjusted Red Marrow Modeling

Purpose: This dosimetry study aimed to evaluate the organ-absorbed doses and safety profile of multiple doses of [177Lu]Ludotadipep, a novel PSMA-targeted radiopharmaceutical with an albumin-binding motif, in patients with metastatic androgen pathway modulator-resistant (mAPMR) prostate cancer. Methods: Twenty patients...

Seunggyun Ha, J. O, Chansoo Park et al. · 0 citations
Sep 2026

Next-Generation Peptide Receptor Radionuclide Therapy: A Phase 1 Dose-Escalation and Dosimetry Study of 177Lu-DOTA-EB-TATE.

Neuroendocrine tumors (NETs) are often detected late, limiting curative treatments and requiring systemic therapies such as peptide receptor radionuclide therapy (PRRT). Although 177Lu-DOTATATE has demonstrated efficacy, its rapid clearance from the circulation limits tumor radiation delivery and may increase renal tox...

L. Bodei, Pat Zanzonico, Simone Krebs et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.